SAN JOSE, Calif., Aug. 13, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical companyfocused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, today announced the pricing of its initial public offering of 2,000,000 shares of its common stock
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Maxim Group LLC is acting as lead manager and Laidlaw & Company (UK) Ltd., Northland Securities, Inc. and Seaport Global Securities LLC are acting as co-managers for the offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on August 13, 2018. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at firstname.lastname@example.org. The registration statement may be obtained free of charge at the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contacts:Tiberend Strategic Advisors, Inc.Jonathon Brzezinski, Ph.D. (Investors)(212) email@example.com
David Schemelia (Media)(212) firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-announces-pricing-of-initial-public-offering-300696436.html
SOURCE Aridis Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!